typhoid

12/12/2018

Nature Communications study addresses MDR typhoid

New study in Nature Communications reveals high burden of multi-drug resistant (MDR) typhoid fever in sub-Saharan Africa associated with two predominant genotypes – IVI epidemiologist Se Eun Park and collaborating scientists report data from Typhoid Fever Surveillance in Africa (TSAP) program and other sources   […]
02/22/2019

Typhoid conjugate vaccine from Indonesia found to be safe, immunogenic in phase 1 clinical trial

    SEOUL, Korea, JAKARTA, Indonesia, February 22, 2019 — Scientists from Bio Farma, the University of Indonesia, and the International Vaccine Institute (IVI), recently published the results of a phase I clinical trial study of a novel typhoid conjugate vaccine involving Indonesian adults and […]
03/05/2019

IVI receives $3.2 million grant to support TCV effectiveness studies in West Africa

  SEOUL, Korea — The International Vaccine Institute (IVI) has been awarded a $3,238,974 grant from the Bill & Melinda Gates Foundation to provide technical assistance support for studies to measure the effectiveness of typhoid conjugate vaccine (TCV) in West Africa. This grant comes after […]
07/25/2019

EuBiologics receives funding from the RIGHT Fund for the development of a cholera conjugate vaccine

      July 25, 2019 – SEOUL, South Korea. The International Vaccine Institute (IVI) is pleased to announce that EuBiologics, IVI’s key partner in Korea, received a 900 million Korean won ($760,000) award from the RIGHT Fund for the development of a cholera conjugate […]
DONATE